USSTOCK.TODAY
Pre-Market
Log in Sign up

Viking Therapeutics to Conduct Four Phase 3 Clinical Trials for Obesity Treatment VK2735

The Motley Fool +1 · ·by G4L

VKTX
VKTX Viking Therapeutics Inc
$26.88 +0.30%
View chart & analysis →
  1. 1Viking Therapeutics is conducting four Phase 3 obesity clinical trials for VK2735.
  2. 2Viking Therapeutics raised net proceeds of $547.8 million through stock issuance and convertible notes.
  3. 3A recent small-scale 33-week maintenance study exploratory cohort recorded a 21.7% weight reduction after 33 weeks.

So what's the key point?

Viking Therapeutics has started obesity treatment trials in four locations. It is important that results showed a 21.7% weight reduction over 33 weeks.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →